The neuropathy in hereditary transthyretin amyloidosis: A narrative review. Issue 2 (11th May 2021)

• Record Type: Journal Article
• Authors: Tozza, Stefano; Severi, Daniele; Spina, Emanuele; Iovino, Aniello; Aruta, Francesco; Ruggiero, Lucia; Dubbioso, Raffaele; Iodice, Rosa; Nolano, Maria; Manganelli, Fiore
• Is Part Of: Journal of the peripheral nervous system. Volume 26:Issue 2(2021)
• Page Start: 155
• Page End: 159
• Publication Date: 2021-05-11
• Subjects: hereditary transthyretin‐mediated amyloidosis -- neuropathology -- neuropathy -- review; Nervous system -- Periodicals; Nerves, Peripheral -- Diseases -- Periodicals; Peripheral Nervous System Diseases -- Periodicals; Peripheral Nervous System -- Periodicals; 612.81
• DOI: 10.1111/jns.12451
• Languages: English
• ISSNs: 1085-9489

Abstract

Abstract: Hereditary transthyretin amyloidosis (ATTRv) is a condition with adult onset, caused by mutation of the transthyretin ( TTR ) gene and characterized by extracellular deposition of amyloid fibrils in tissue, especially in the peripheral nervous system (PNS) and heart. PNS involvement leads to a rapidly progressive and disabling sensory‐motor axonal neuropathy. Although awareness among neurologists increased in recent years thanks to new treatment options, ATTRv is frequently misdiagnosed, and thus a correct diagnosis can be delayed by several years. This review aims to draw the history and features of polyneuropathy in ATTRv based on pathological and electrophysiological correlates. We assessed original articles and case reports based on their relevance to ATTRv neuropathy and we included those appropriate for the scheme of this narrative review. Amyloid fibrils initially deposit in ganglia, causing an axonal neuropathy without amyloid deposits in distal segments (eg, sural nerve biopsy). Over time, amyloid fibrils spread along the nerves, leading to some demyelinating features in the context of severe axonal loss. This review highlights how the features of neuropathy change based on type of ATTRv (early vs late onset) and stage of disease.